| 18477-0 |
Lithium |
SRat |
Urine |
24H |
Qn |
|
|
ACTIVE |
Lithium [Moles/time] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/24 H |
|
|
|
|
|
|
DRUG/TOX |
|
18477-0 |
|
|
|
|
Both |
|
|
|
0 |
Lithium 24h Ur-sRate |
|
|
|
Y |
|
1 day; 24 hours; 24HR; DRUG/TOXICOLOGY; Drugs; Eskalith; Li; Lithane; QNT; Quan; Quant; Quantitative; sRate; Substance Rate; UA; UR; Urn |
2.77 |
1.0l |
|
|
|
|
|
|
|
mmol/(24.h) |
|
|
|
0 |
| 18478-8 |
Human papilloma virus 16+18 DNA |
PrThr |
Tiss |
Pt |
Ord |
Probe |
|
ACTIVE |
Human papilloma virus 16+18 DNA [Presence] in Tissue by Probe |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
18478-8 |
|
Probe |
|
|
Both |
|
|
|
0 |
HPV16+18 DNA Tiss Ql Probe |
|
|
|
|
|
Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Genital warts; HPV; HPV16; HPV16 and 18; HPV16 and 18 DNA; HPV16+18; Human papillomavirus; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Papilloma virus high risk; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 18479-6 |
Human papilloma virus 31+35+51 DNA |
PrThr |
Tiss |
Pt |
Ord |
Probe |
|
ACTIVE |
Human papilloma virus 31+35+51 DNA [Presence] in Tissue by Probe |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
18479-6 |
|
Probe |
|
|
Both |
|
|
|
0 |
HPV31+35+51 DNA Tiss Ql Probe |
|
|
|
|
|
Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Genital warts; HPV; HPV31; HPV31+35+51; Human papillomavirus; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Papilloma virus high risk; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 1848-1 |
Androstanolone |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Androstanolone [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/dL; pg/mL |
|
|
|
|
|
|
CHEM |
|
1848-1 |
|
|
|
|
Both |
|
|
|
0 |
Androstanolone SerPl-mCnc |
|
|
|
Y |
|
Chemistry; DHT; Dihydrotestosterone; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UniversalLabOrders |
2.73 |
1 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
| 18480-4 |
Human papilloma virus 6+11 DNA |
PrThr |
Tiss |
Pt |
Ord |
Probe |
|
ACTIVE |
Human papilloma virus 6+11 DNA [Presence] in Tissue by Probe |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
18480-4 |
|
Probe |
|
|
Both |
|
|
|
0 |
HPV6+11 DNA Tiss Ql Probe |
|
|
|
|
|
Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Genital warts; HPV; HPV6; HPV6+11; Human papillomavirus; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Papilloma virus low risk; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 18481-2 |
Streptococcus pyogenes Ag |
PrThr |
Thrt |
Pt |
Ord |
|
|
ACTIVE |
Streptococcus pyogenes Ag [Presence] in Throat |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
18481-2 |
|
|
|
|
Both |
|
|
|
0 |
S pyo Ag Throat Ql |
|
|
|
|
|
Antigen; Antigens; GAS; Group A Strep; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; S pyogenes; Screen; Steptococcus Group A; Strep; Strept; Streptococci group A; Streptococcus group A; Throat; UniversalLabOrders; Upper respiratory |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
43 |
| 18482-0 |
Yeast |
PrThr |
XXX |
Pt |
Ord |
Organism specific culture |
|
ACTIVE |
Yeast [Presence] in Specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
18482-0 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Yeast Spec Ql Cult |
|
|
|
|
|
C&S; Cult; Cultures; ID; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; UniversalLabOrders; Unspecified |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 18483-8 |
Yeast |
PrThr |
Genital |
Pt |
Ord |
Organism specific culture |
|
ACTIVE |
Yeast [Presence] in Genital specimen by Organism specific culture |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
18483-8 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
Yeast Genital Ql Cult |
|
|
|
|
|
C&S; Cult; Cultures; Gen; Genital tract; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spec; Urogenit; Urogenital |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 18484-6 |
Ku Ab |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Ku Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
18484-6 |
|
|
|
|
Both |
|
|
|
0 |
Ku Ab Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 18485-3 |
Mi-2 Ab |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Mi-2 Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
18485-3 |
|
|
|
|
Both |
|
|
|
0 |
MI2 Ab Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; CHD2; Chromodomain-helicase-DNA-binding protein 2; II; MI2; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serology; Serum; SR |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 18486-1 |
Methylenediamine |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Methylenediamine [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
18486-1 |
|
|
|
|
Both |
|
|
|
0 |
Me-enediam Ur Ql |
|
|
|
|
|
DRUG/TOXICOLOGY; Drugs; MDA; Me-enediam; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 18487-9 |
Broad casts |
Naric |
Urine sed |
Pt |
Qn |
Microscopy.light.LPF |
|
ACTIVE |
Broad casts [#/area] in Urine sediment by Microscopy low power field |
|
MIN |
DefinitionDescription |
|
|
/LPF |
|
|
|
|
|
|
UA |
|
18487-9 |
|
Microscopy.light.LPF |
|
|
Observation |
|
|
|
0 |
Broad Casts #/area UrnS LPF |
|
|
|
Y |
|
#/area; Cast; Kidney; LM; Micro; Micros; Microscopic; Nephrology; Number areic; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; Renal failure casts; UA; UR; URINALYSIS; Urine sediment; Urn; UrnS |
2.73 |
1.0l |
|
|
|
|
|
|
|
/[LPF] |
|
|
|
0 |
| 18488-7 |
Calcium |
MCnc |
Urine |
24H |
Qn |
|
|
ACTIVE |
Calcium [Mass/volume] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
mg/dL; mg/L |
|
|
|
|
|
|
CHEM |
|
18488-7 |
|
|
|
|
Both |
|
|
|
0 |
Calcium 24h Ur-mCnc |
|
|
|
Y |
|
1 day; 24 hours; 24HR; Ca; Cal; Chemistry; Kidney; Level; Mass concentration; Nephrology; QNT; Quan; Quant; Quantitative; Renal; UA; UniversalLabOrders; UR; Urn |
2.73 |
1.0l |
|
|
|
|
|
|
|
mg/L |
|
|
|
0 |
| 18489-5 |
Valproate.protein bound |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Valproate.protein bound [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
18489-5 |
|
|
|
|
Both |
|
|
|
0 |
PB Valproate SerPl-mCnc |
|
|
|
Y |
|
Associated; bnd; Depakene; Divalproex; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; PB Valproate; Pl; Plasma; Plsm; Point in time; PR; Prot; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; VALP; Valproic acid |
2.73 |
1.0l |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 1849-9 |
Androstanolone |
MCnc |
Semen |
Pt |
Qn |
|
|
ACTIVE |
Androstanolone [Mass/volume] in Semen |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHEM |
|
1849-9 |
|
|
|
|
Both |
|
|
|
0 |
Androstanolone Smn-mCnc |
|
|
|
Y |
|
Chemistry; DHT; Dihydrotestosterone; Ejaculate; Genitourinary; GU; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Sem; Seminal fluid; Smn; SMPLS; URO; Urology |
2.42 |
1 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
| 18490-3 |
Chlamydia trachomatis G+F+K Ab.IgA |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Chlamydia trachomatis G+F+K IgA Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
18490-3 |
|
IF |
|
|
Both |
|
|
|
0 |
C trach G+F+K IgA Titr Ser IF |
|
|
|
Y |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; C trac; C trach; C trach G+F+K; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; Chlamydia trachomatis type G+F+K; CT; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin A; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin A; Infectious Disease; InfectiousDisease; Intermediate; Kell Blood Group System; LGV; Lymphogranuloma venereum; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; Trachoma; TRF; Ttr |
2.75 |
1.0l |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 18491-1 |
Chlamydia trachomatis G+F+K Ab.IgG |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Chlamydia trachomatis G+F+K IgG Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
18491-1 |
|
IF |
|
|
Both |
|
|
|
0 |
C trach G+F+K IgG Titr Ser IF |
|
|
|
Y |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; C trac; C trach; C trach G+F+K; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; Chlamydia trachomatis type G+F+K; CT; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Intermediate; Kell Blood Group System; LGV; Lymphogranuloma venereum; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; Trachoma; TRF; Ttr |
2.75 |
1.0l |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 18492-9 |
Chlamydia trachomatis G+F+K Ab.IgM |
Titr |
Ser |
Pt |
SemiQn |
IF |
|
ACTIVE |
Chlamydia trachomatis G+F+K IgM Ab [Titer] in Serum by Immunofluorescence |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
18492-9 |
|
IF |
|
|
Both |
|
|
|
0 |
C trach G+F+K IgM Titr Ser IF |
|
|
|
Y |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; C trac; C trach; C trach G+F+K; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; Chlamydia trachomatis type G+F+K; CT; Dilution factor; Dilution Factor (Titer); FA; Fluorescent antibody; Fluoresent; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Intermediate; Kell Blood Group System; LGV; Lymphogranuloma venereum; Microbiology; Point in time; Random; Serum; SmQn; SR; Time Resolved Fluorescence; Titer; Titered; Titre; Trachoma; TRF; Ttr |
2.75 |
1.0l |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
| 18493-7 |
Ova & parasites^3rd specimen |
Prid |
Stool |
Pt |
Nom |
Concentration |
|
ACTIVE |
Ova and parasites identified in Stool by Concentration--3rd specimen |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
18493-7 |
|
Concentration |
|
|
Both |
|
|
|
0 |
O+P sp3 Stl Conc |
|
|
|
|
|
Bowel movement; Cnc; Conc; Faecal; Faeces; Fecal; Feces; Gastro; Gastroenterology; GI; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; O&P; O+P; Ova and parasite; Ovum; Parasite; Point in time; Random; sp3; Spec; Stl; Stool = Fecal |
2.78 |
1.0l |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
| 18494-5 |
Ova & parasites^2nd specimen |
Prid |
Stool |
Pt |
Nom |
Concentration |
|
ACTIVE |
Ova and parasites identified in Stool by Concentration--2nd specimen |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
18494-5 |
|
Concentration |
|
|
Both |
|
|
|
0 |
O+P sp2 Stl Conc |
|
|
|
|
|
Bowel movement; Cnc; Conc; Convalescent; Faecal; Faeces; Fecal; Feces; Gastro; Gastroenterology; GI; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; O&P; O+P; Ova and parasite; Ovum; Parasite; Point in time; Post immunization; Random; Second; sp2; Spec; Stl; Stool = Fecal |
2.78 |
1.0l |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
| 18495-2 |
Ova & parasites^3rd specimen |
Prid |
Stool |
Pt |
Nom |
Trichrome stain |
|
ACTIVE |
Ova and parasites identified in Stool by Trichrome stain--3rd specimen |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
18495-2 |
|
Trichrome stain |
|
|
Both |
|
|
|
0 |
O+P sp3 Stl Tri Stn |
|
|
|
|
|
Bowel movement; Faecal; Faeces; Fecal; Feces; Gastro; Gastroenterology; GI; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; O&P; O+P; Ova and parasite; Ovum; Parasite; Point in time; Random; sp3; Spec; St; Stains; Stl; Stn; Stool = Fecal; Tri Stn |
2.78 |
1.0l |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
| 18496-0 |
Ova & parasites^2nd specimen |
Prid |
Stool |
Pt |
Nom |
Trichrome stain |
|
ACTIVE |
Ova and parasites identified in Stool by Trichrome stain--2nd specimen |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
18496-0 |
|
Trichrome stain |
|
|
Both |
|
|
|
0 |
O+P sp2 Stl Tri Stn |
|
|
|
|
|
Bowel movement; Convalescent; Faecal; Faeces; Fecal; Feces; Gastro; Gastroenterology; GI; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; O&P; O+P; Ova and parasite; Ovum; Parasite; Point in time; Post immunization; Random; Second; sp2; Spec; St; Stains; Stl; Stn; Stool = Fecal; Tri Stn |
2.78 |
1.0l |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Removed "Identified" from the component because it is implied by the Property "Prid"; |
0 |
| 18497-8 |
Observation |
Prid |
Thyroid.FNA |
Pt |
Nom |
Cyto stain |
|
ACTIVE |
Microscopic observation [Identifier] in Thyroid fine needle aspirate by Cyto stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CYTO |
|
18497-8 |
|
Cyto stain |
|
|
Both |
|
|
|
0 |
Cyto Thyroid FNA |
|
|
|
|
|
CYTOLOGY; Cytology stain; Cytostain; Fine needle; Identity or presence; Nominal; Pap Smear; Pap Stain; Papanicolaou smear; Point in time; Random; St; Stains; Stn; Thy; Thyroid FNA |
2.78 |
1.0l |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
| 18498-6 |
Observation |
Prid |
Breast.FNA |
Pt |
Nom |
Cyto stain |
|
ACTIVE |
Microscopic observation [Identifier] in Breast fine needle aspirate by Cyto stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CYTO |
|
18498-6 |
|
Cyto stain |
|
|
Both |
|
|
|
0 |
Cyto Breast FNA |
|
|
|
|
|
Breast FNA; Brst; CYTOLOGY; Cytology stain; Cytostain; Fine needle; Identity or presence; Nominal; Pap Smear; Pap Stain; Papanicolaou smear; Point in time; Random; St; Stains; Stn |
2.78 |
1.0l |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
| 18499-4 |
Observation |
Prid |
Nipple discharge |
Pt |
Nom |
Cyto stain |
|
ACTIVE |
Microscopic observation [Identifier] in Nipple discharge by Cyto stain |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CYTO |
|
18499-4 |
|
Cyto stain |
|
|
Both |
|
|
|
0 |
Cyto Nipple dis |
|
|
|
|
|
CYTOLOGY; Cytology stain; Cytostain; Disch; Identity or presence; Nominal; Pap Smear; Pap Stain; Papanicolaou smear; Point in time; Random; St; Stains; Stn |
2.78 |
1.0l |
|
|
|
|
|
|
|
|
|
|
Release 2.78: COMPONENT: Updated to seperate the component from the method; |
0 |
